Monge L, De Mattei M, Dani F, Sciarretta A, Carta Q
Division of Diabetology, Azienda Ospedaliera San Giovanni Battista di Torino, Italy.
Diabet Med. 1995 Dec;12(12):1097-101. doi: 10.1111/j.1464-5491.1995.tb00427.x.
The aim of this study was to test the efficacy of the aldose-reductase inhibitor Tolrestat in the treatment of carpal tunnel syndrome in Type 2 diabetic patients. Seventeen patients were treated with Tolrestat (200 mg daily for 12 months) clinical and neurophysiological evaluations were performed at baseline, 6 and 12 months; symptoms and blood glucose control were assessed at baseline, 2, 6, and 12 months. Thirteen Type 2 diabetic patients suffering from symptomatic carpal tunnel syndrome served as controls. Neurophysiological studies showed improvement in the sensory conduction velocity of the median nerve between forefinger and wrist (baseline 37.5 +/- 4.3 vs 6 months 41.3 +/- 5.7 ms-1, p < 0.0005 and baseline vs 12 months 41.4 +/- 8.2 ms-1, p < 0.005) but not between wrist and elbow. The terminal latency index of the median nerve was unchanged. Paraesthesiae and pain improved in terms of intensity and frequency. Blood glucose control was not significantly changed. We conclude that treatment of this case series with Tolrestat appears to produce beneficial effect on the outcome of carpal tunnel syndrome in diabetic patients.
本研究旨在测试醛糖还原酶抑制剂托瑞司他治疗2型糖尿病患者腕管综合征的疗效。17例患者接受托瑞司他治疗（每日200mg，共12个月），在基线、6个月和12个月时进行临床和神经生理学评估；在基线、2个月、6个月和12个月时评估症状和血糖控制情况。13例患有症状性腕管综合征的2型糖尿病患者作为对照。神经生理学研究显示，示指与腕部之间正中神经的感觉传导速度有所改善（基线时为37.5±4.3，6个月时为41.3±5.7m/s，p<0.0005；基线与12个月时相比为41.4±8.2m/s，p<0.005），但腕部与肘部之间未改善。正中神经的终末潜伏期指数未改变。感觉异常和疼痛在强度和频率方面有所改善。血糖控制无显著变化。我们得出结论，用托瑞司他治疗该病例系列似乎对糖尿病患者腕管综合征的预后产生有益影响。
